Relugolix

Relugolix combination therapy may be an effective and safe long-term treatment option for premenopausal women with endometriosis and nonmenstrual pelvic pain, researchers reported in Human Reproduction.

Once-daily relugolix combination therapy reduced heavy menstrual bleeding associated with uterine fibroids for most Black women, according to results of the LIBERTY long-term extension study.

At 2 years, women who had received relugolix combination therapy for 52 weeks and then withdrew therapy continued to have less menstrual blood loss and pain caused by uterine fibroids, researchers reported.

Healio spoke with Shawana S. Moore, DNP, MSN, APRN, CRNP, WHNP-BC, about currently available treatment options for endometriosis as well as newer and emerging therapeutics.

The Healio editors have compiled the most read news from the NAMS annual meeting in October.

Potentially perimenopausal women who took relugolix combination therapy for uterine fibroids and heavy menstrual bleeding experienced significant reductions in menstrual bleeding and fibroid-related pain vs. those who took placebo.

The FDA approved Myfembree for the management of moderate to severe pain associated with endometriosis, according to a press release from Myovant Sciences.

SAN DIEGO — About 70% of women with uterine fibroid-related heavy menstrual bleeding who took relugolix combination therapy experienced amenorrhea, according to data presented at the ACOG Annual Clinical & Scientific Meeting.

Once-daily treatment with a combination of relugolix, estradiol and norethindrone acetate significantly reduced menstrual bleeding with uterine fibroids, according to two randomized studies published in The New England Journal of Medicine.

The FDA approved relugolix for the treatment of men with advanced prostate cancer.